Inflammatory bowel disease in the pediatric and adolescent patient

C. Cuffari, A. Darbari

Research output: Contribution to journalArticle

Abstract

Advances in genetic testing have confirmed the presence of susceptibility loci on chromosomes 12 and 16 for UC and CD. These loci show a strong association with particular disease phenotypes that may explain the clinical heterogeneity of IBD. Whether multiple genotypes will be found to explain these phenotypes remains to be determined. Pharmacogenetic differences in 6-mercaptopurine metabolism can be used clinically to predict patient susceptibility to drug-induced toxicity. Novel treatment strategies are being developed at The Johns Hopkins Medical Center Hospital based on these inherent genetic differences. The aim is to improve treatment efficacy and clinical response times and prevent untoward drug-induced toxicity.

Original languageEnglish (US)
Pages (from-to)275-291
Number of pages17
JournalGastroenterology Clinics of North America
Volume31
Issue number1
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Inflammatory bowel disease in the pediatric and adolescent patient'. Together they form a unique fingerprint.

  • Cite this